StreetInsider.com News Articles

Alpha Teknova Inc. (TKNO) PT Raised to $11 at TD Cowen

Tue, 13 Oct 2026 09:39:22 -0400

TD Cowen analyst Brendan Smith raised the price target on Alpha Teknova Inc. (NASDAQ: TKNO) to $11.00 (from $7.00) while maintaining a rating.

Teknova and Pluristyx file FDA drug master file for PluriFreeze system

Fri, 02 Oct 2026 16:02:25 -0400

Alpha Teknova, Inc. (Nasdaq: TKNO) and Pluristyx, Inc. announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration.

The DMF will allow drug developers using PluriFreeze during preclinical stages to request a letter of authorization from Pluristyx and cross-reference the file in Investigational New Drug applications and Biologics License Applications. The submission covers chemistry, manufacturing, and controls documentation for the PluriFreeze system.

"The PluriFreeze DMF gives advanced therapy developers more to build on than strong product performance: a documented regulatory position for their cryopreservation system, ready

Teknova and Pluristyx file FDA drug master file for PluriFreeze system

Fri, 02 Oct 2026 16:02:25 -0400

"The PluriFreeze DMF gives advanced therapy developers more to build on than strong product performance: a documented regulatory position for their cryopreservation system, ready

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Fri, 02 Oct 2026 16:01:00 -0400

Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissions

HOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc. (“Pluristyx”), today announced that Pluristyx is completing a Type II Drug Master File (DMF) for the PluriFreeze™ cryopreservation system for submission to the U.S. Food and Drug Administration (FDA). The DMF will support drug makers seeking to incorporate PluriFreeze into their clinical development and manufacturing programs. Teknova is a leading producer of critical reagents for the discovery,

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Fri, 02 Oct 2026 16:01:00 -0400

Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissions

Jefferies Starts Alpha Teknova Inc. (TKNO) at Buy

Thu, 17 Sep 2026 02:49:12 -0400

Jefferies analyst Matthew Stanton initiates coverage on Alpha Teknova Inc. (NASDAQ: TKNO) with a Buy rating and a price target of $9.00.

The analyst comments: “TKNO is emerging player offering RUO and GMP products to variety of attractive life science and diagnostics applications. We see plenty of growth ahead, with upside tied to biotech funding (2H26 and beyond), recent commercial investment (early '27) and clinical pipeline (2027+). This demand will support significant GM ramp (from ~40% today to 55-60%), with upside to both '27 (+100bps) & '28 (+300-400bps), in our view. Initiate at Buy, $9 PT = 9x '27E EV/ revs.

TKNO's

Jefferies Starts Alpha Teknova Inc. (TKNO) at Buy

Thu, 17 Sep 2026 02:49:12 -0400

Jefferies analyst Matthew Stanton initiates coverage on Alpha Teknova Inc. (NASDAQ: TKNO) with a Buy rating and a price target of $9.00.

TKNO's

Teknova launches Fill-Tek dispensing system for single-use bag filling

Wed, 16 Sep 2026 17:31:16 -0400

Alpha Teknova, Inc. (Nasdaq: TKNO) introduced the Fill-Tek™ Dispensing System, a proprietary single-use bag dispensing capability that allows customers to order custom reagent combinations across multiple bag sizes and quantities as a single lot with one Certificate of Analysis.

According to a company press release, Fill-Tek removes per-bag-size minimums associated with fixed manifold designs by using validated aseptic welds to connect a customer's specified combination of single-use bags to a dispensing vessel, filling them from a single batch through a single filter.

Customers can specify bag sizes ranging from 250 mL to 200 L, and customize fill volume, number, size, and sequence

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Wed, 16 Sep 2026 17:30:00 -0400

Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround time

HOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Wed, 16 Sep 2026 17:30:00 -0400

BTIG Upgrades Alpha Teknova Inc. (TKNO) to Buy following earnings

Tue, 11 Aug 2026 05:48:19 -0400

BTIG analyst Mark Massaro upgraded Alpha Teknova Inc. (NASDAQ: TKNO) from Neutral to Buy with a price target of $8.00.

The analyst comments "We upgrade Alpha Teknova from a Neutral to a Buy rating and establish a price target of $8.00/share. TKNO delivered a top- and bottom-line beat in Q2'26, and raised its 2026 revenue guidance on improving fundamentals in its business on the back of an improving funding environment in life sciences. Unlike in recent prior years, TKNO is now driving broad-based double-digit revenue growth across both of its key segments at a rate of +18% Y/Y, and we think

BTIG Upgrades Alpha Teknova Inc. (TKNO) to Buy following earnings

Tue, 11 Aug 2026 05:48:19 -0400

BTIG analyst Mark Massaro upgraded Alpha Teknova Inc. (NASDAQ: TKNO) from Neutral to Buy with a price target of $8.00.

Form 10-Q Alpha Teknova, Inc. For: Jun 30

Thu, 06 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260806/26884614.html

Form 10-Q Alpha Teknova, Inc. For: Jun 30

Thu, 06 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260806/26884614.html

Alpha Teknova, Inc. (TKNO) Tops Q2 EPS by 2c

Wed, 05 Aug 2026 17:39:11 -0400

Alpha Teknova, Inc. (NASDAQ: TKNO) reported Q2 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $10.98 million.

For earnings history and earnings-related data on Alpha Teknova, Inc. (TKNO) click here.

Form 8-K Alpha Teknova, Inc. For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874056.html

Form 8-K Alpha Teknova, Inc. For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874056.html

Teknova Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year
Company raises 2026 revenue guidance to $45-47 million
Launched proprietary AI-powered Build-Tek™ custom order configurator, giving developers a faster path from preclinical to clinical manufacturing

HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2026.

"We delivered more than $12 million

Teknova Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:01:00 -0400

"We delivered more than $12 million

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

Wed, 05 Aug 2026 08:59:00 -0400

Therapeutic and diagnostic developers gain flexibility, speed, and scalability to advance custom formulations from preclinical research to manufacturing for clinical trials, with a reviewed quote returned in under three business days

HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched Build-Tek™, an AI-powered custom order configurator that enables developers of therapies and diagnostics to design complex custom products and submit a request for quote in minutes. Build-Tek expands on the original buffer configurator

Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes

Wed, 05 Aug 2026 08:59:00 -0400

Roth/MKM Starts Alpha Teknova Inc. (TKNO) at Buy

Wed, 05 Aug 2026 02:56:47 -0400

Roth/MKM analyst Max Masucci initiates coverage on Alpha Teknova Inc. (NASDAQ: TKNO) with a Buy rating and a price target of $7.00.

The analyst comments: “TKNO provides diversified exposure to several key growth offshoots within life sciences markets and serves 3,300+ customers across biotech, advanced therapies, "omic" tools, and diagnostics (with 95%+ customer retention). With strong incremental gross margins (~70%), a recovering biotech/biopharma funding backdrop, and the advancement of its customers' clinical solutions toward commercialization, we see a favorable 2026-2028 setup for top-line growth and progress towards breakeven.

TKNO produces critical reagents that enable the discovery, development, and commercialization of therapies, vaccines,

Roth/MKM Starts Alpha Teknova Inc. (TKNO) at Buy

Wed, 05 Aug 2026 02:56:47 -0400

Roth/MKM analyst Max Masucci initiates coverage on Alpha Teknova Inc. (NASDAQ: TKNO) with a Buy rating and a price target of $7.00.

TKNO produces critical reagents that enable the discovery, development, and commercialization of therapies, vaccines,

Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 16:01:00 -0400

HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market.

Teknova will host a webcast and conference call on Wednesday, August 5, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the

Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 16:01:00 -0400

Teknova will host a webcast and conference call on Wednesday, August 5, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the